Hangzhou Tigermed Consulting Co., Ltd. (300347.SZ)
CNY 44.64
(-1.28%)
CNY 44.64
(-1.28%)
| Year | Inventory | Inventory Growth |
|---|---|---|
| 2023 | 23.39 Million CNY | 5.37% |
| 2022 | 22.2 Million CNY | 264.3% |
| 2021 | 6.09 Million CNY | 29.1% |
| 2020 | 4.72 Million CNY | 291.61% |
| 2019 | 1.2 Million CNY | 132.34% |
| 2018 | 518.89 Thousand CNY | 3598.71% |
| 2017 | 14.02 Thousand CNY | -76.57% |
| 2016 | 59.87 Thousand CNY | -86.31% |
| 2015 | 437.25 Thousand CNY | 48.0% |
| 2014 | 295.45 Thousand CNY | -16.85% |
| 2013 | 355.3 Thousand CNY | 32.22% |
| 2012 | 268.72 Thousand CNY | 182.07% |
| 2011 | 95.26 Thousand CNY | 118.6% |
| 2010 | 43.58 Thousand CNY | 0.0% |
| 2009 | - CNY | 0.0% |
| Year | Inventory | Inventory Growth |
|---|---|---|
| 2024 Q1 | 94.25 Million CNY | 302.82% |
| 2024 Q2 | 22.13 Million CNY | -76.51% |
| 2024 Q3 | 22.19 Million CNY | 0.27% |
| 2023 Q2 | 26.53 Million CNY | 14.74% |
| 2023 Q4 | 23.39 Million CNY | -14.1% |
| 2023 FY | 23.39 Million CNY | 5.37% |
| 2023 Q3 | 27.23 Million CNY | 2.65% |
| 2023 Q1 | 23.12 Million CNY | 4.15% |
| 2022 Q3 | 35.09 Million CNY | 106.86% |
| 2022 Q2 | 16.96 Million CNY | 121.99% |
| 2022 Q4 | 22.2 Million CNY | -36.73% |
| 2022 Q1 | 7.64 Million CNY | 25.38% |
| 2022 FY | 22.2 Million CNY | 264.3% |
| 2021 Q3 | 5.88 Million CNY | 6.56% |
| 2021 FY | 6.09 Million CNY | 29.1% |
| 2021 Q2 | 5.52 Million CNY | 4.99% |
| 2021 Q4 | 6.09 Million CNY | 3.53% |
| 2021 Q1 | 5.26 Million CNY | 11.47% |
| 2020 Q1 | 2.41 Million CNY | 100.11% |
| 2020 Q3 | 1.55 Million CNY | 19.77% |
| 2020 FY | 4.72 Million CNY | 291.61% |
| 2020 Q4 | 4.72 Million CNY | 204.06% |
| 2020 Q2 | 1.29 Million CNY | -46.26% |
| 2019 Q2 | 626.18 Thousand CNY | 7.8% |
| 2019 Q4 | 1.2 Million CNY | 74.89% |
| 2019 FY | 1.2 Million CNY | 132.34% |
| 2019 Q1 | 580.89 Thousand CNY | 11.95% |
| 2019 Q3 | 689.34 Thousand CNY | 10.09% |
| 2018 Q4 | 518.89 Thousand CNY | 51.11% |
| 2018 FY | 518.89 Thousand CNY | 3598.71% |
| 2018 Q3 | 343.39 Thousand CNY | -68.76% |
| 2018 Q2 | 1.09 Million CNY | 6143.74% |
| 2018 Q1 | 17.6 Thousand CNY | 25.5% |
| 2017 FY | 14.02 Thousand CNY | -76.57% |
| 2017 Q1 | 65.98 Thousand CNY | 10.19% |
| 2017 Q2 | 71.77 Thousand CNY | 8.79% |
| 2017 Q4 | 14.02 Thousand CNY | -77.31% |
| 2017 Q3 | 61.82 Thousand CNY | -13.86% |
| 2016 Q4 | 59.87 Thousand CNY | -81.53% |
| 2016 Q3 | 324.17 Thousand CNY | -4.34% |
| 2016 Q2 | 338.87 Thousand CNY | -58.16% |
| 2016 FY | 59.87 Thousand CNY | -86.31% |
| 2016 Q1 | 810.01 Thousand CNY | 85.25% |
| 2015 Q2 | 271.77 Thousand CNY | -59.32% |
| 2015 Q3 | 488.44 Thousand CNY | 79.73% |
| 2015 Q4 | 437.25 Thousand CNY | -10.48% |
| 2015 Q1 | 668.13 Thousand CNY | 126.14% |
| 2015 FY | 437.25 Thousand CNY | 48.0% |
| 2014 Q1 | 223.36 Thousand CNY | -37.13% |
| 2014 Q4 | 295.45 Thousand CNY | 23.13% |
| 2014 Q3 | 239.95 Thousand CNY | -43.36% |
| 2014 Q2 | 423.67 Thousand CNY | 89.67% |
| 2014 FY | 295.45 Thousand CNY | -16.85% |
| 2013 Q1 | 139.94 Thousand CNY | -47.92% |
| 2013 FY | 355.3 Thousand CNY | 32.22% |
| 2013 Q4 | 355.3 Thousand CNY | 214.33% |
| 2013 Q3 | 113.03 Thousand CNY | -4.55% |
| 2013 Q2 | 118.42 Thousand CNY | -15.38% |
| 2012 Q4 | 268.72 Thousand CNY | 10.86% |
| 2012 FY | 268.72 Thousand CNY | 182.07% |
| 2012 Q2 | 94.35 Thousand CNY | 0.0% |
| 2012 Q3 | 242.39 Thousand CNY | 156.91% |
| 2011 Q4 | 95.26 Thousand CNY | 0.0% |
| 2011 FY | 95.26 Thousand CNY | 118.6% |
| 2010 FY | 43.58 Thousand CNY | 0.0% |
| 2009 FY | - CNY | 0.0% |
| Name | Inventory | Inventory Difference |
|---|---|---|
| Dian Diagnostics Group Co.,Ltd. | 1.5 Billion CNY | 98.449% |
| Dirui Industrial Co.,Ltd. | 572.93 Million CNY | 95.916% |
| Beijing Strong Biotechnologies, Inc. | 229.74 Million CNY | 89.816% |
| Medicalsystem Biotechnology Co., Ltd. | 259.01 Million CNY | 90.967% |
| Maccura Biotechnology Co.Ltd | 907.48 Million CNY | 97.422% |
| Guangzhou Wondfo Biotech Co.,Ltd | 351.4 Million CNY | 93.342% |
| Guangdong Hybribio Biotech Co.,Ltd. | 99.55 Million CNY | 76.498% |
| BGI Genomics Co., Ltd. | 602.18 Million CNY | 96.115% |
| Amoy Diagnostics Co., Ltd. | 28.78 Million CNY | 18.709% |
| Shanghai Labway Clinical Laboratory Co., Ltd. | 367.71 Million CNY | 93.637% |